Drug Type Small molecule drug |
Synonyms Alvaiz |
Target |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (29 Nov 2023), |
Regulation- |
Molecular FormulaC30H35N5O5 |
InChIKeyXSHFVAAXJHNDKZ-OUFJFOJPSA-M |
CAS Registry2336813-25-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | US | 29 Nov 2023 | |
Thrombocytopenia | US | 29 Nov 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Phase 2 | US | 01 Oct 2013 | |
Leukemia | Phase 2 | US | 01 Oct 2013 | |
Myelodysplastic Syndromes | Phase 2 | US | 01 Oct 2013 | |
Myelodysplastic Syndromes | Phase 2 | US | 01 Oct 2013 |
Phase 2 | 29 | (Eltrombopag) | kiqynocuhc(czspnvqnkd) = jwohwapbzh xmhaxvqfqa (ygyhgzvtol, mrtrgakdge - rdnhqznlyt) View more | - | 18 Feb 2020 | ||
Hypomethylating Agent (HMA)+Eltrombopag (Eltrombopag + Hypomethylating Agent (HMA)) | kiqynocuhc(czspnvqnkd) = jwsegsfrag xmhaxvqfqa (ygyhgzvtol, iswmhtbaqw - puyhrijwnc) View more |